Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology
Disease Category: Depression (Major/Severe)
Trial Information
Evaluation of the safety and tolerability of GSK163090 at single and repeat doses in subjects with MDD.
Study to evaluate the safety and tolerability of an
investigational medication at single and repeat doses in
individuals with Major Depressive Disorder (MDD).
Patient Inclusion Criteria
- Male or females age 18 - 65
- Diagnosis of depression.
- Non-smoker or light (<10 cigarettes per day) smoker.
- Able to complete 10 overnight stays in our inpatient
facility.
Patient Exclusion Criteria:
- History of drug or alcohol abuse.
- History of hepatitis.
Christina Kiecker, Recruitment Coordinator
Clinical Research Institute
201 S. Hillside
Wichita, KS 67211
Phone: 316-293-1833
EMail: ckiecker@cri-research.net
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
